Colontown is an online community of more than 100 private Facebook groups for colorectal cancer patients, survivors, and care partners. The purpose of this study is document and analyze Colontown members' engagement practices and perceptions of patient empowerment, to determine how online communities can support patients and caregivers in CRC management.

The purpose of this single-arm phase 2 study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

To compare the prevalence, severity, and timing of chronic health conditions (CHC) in a cohort of patients with DS-AL (Down Syndrome Acute Leukemia) with age-comparable DS individuals that have no cancer history. Our secondary objectives will compare NP (Neuro-Psychological) and health-related quality of life outcomes in survivors of DS-AL compared with age-comparable DS individuals with no cancer history, and will identify risk determinants of CHC and NP late effects among survivors of DS-AL.

The aim of this study for low and standard risk germ cell tumor (GCT) patients is to minimize toxicity by reducing therapy while maintaining current survival rates. The trial will eliminate chemotherapy for low risk patients who are likely cured with surgery and will observe the salvage rates among those who recur.

We are surveying families of pediatric hematology/oncology patients to find out their interest in and use of integrative and complementary health practices.

The purpose of this research study is to assess the patient-level, healthcare provider/system-level, and community-level barriers to resolving abnormal mammograms and initiation of treatment of breast cancer in the 3 geographic regions of North Carolina: the greater Charlotte area, the Northwest, and the Northeast. These areas include the following counties: Anson, Cabarrus, Cleveland, Gaston, Lincoln, Mecklenburg, Stanly, Union, Edgecombe, Halifax, Nash, Northampton, Wilson , Ashe, Alleghany, Surry, Stokes, Watauga, Wilkes, Yadkin, Forsyth, Avery, Caldwell, Alexander, Iredell, Davie, Davidson, Burke, Catawba, and Rowan. These barriers can include obtainment of biopsies and other diagnostic procedures for resolving abnormal mammograms abnormalities or breast symptoms, access to care providers after breast cancer diagnosis, and initiation of appropriate surgical, chemotherapy, and radiation treatments after diagnosis.

The purpose of the study is to determine whether the continuing detection of cell-free plasma tumor DNA (ptDNA), circulating tumor cells (CTCs), and cytokines (chemicals that help the immune system communicate) in the blood can help to better evaluate the status of a patients cancer over the course of therapy.

This study aims to design and improve tools that can be used to select strategies for improving colorectal cancer screening in different settings and populations. Interviews, surveys, and focus groups will be conducted with individuals who make decisions related to colorectal cancer screening interventions about their understanding, preferences, and suggestions related to these tools and intervention strategies.

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

The purpose of this study is to understand how your gut plays a role in how well CAR T cell therapy works. Your gut is home to bacteria, which we call the gut microbiome. The gut microbiome can send signals to your immune cells, which may impact how well and how long CAR T cell therapy will last. We can find out what type of bacteria are in your gut microbiome by studying your stool. We can understand more about the signals sent to the immune system by studying your blood. We will ask for stool and blood at the same time points throughout your treatment. We will study the identities and function of the bacteria and immune cells to understand more about how these signals work during CAR T cell treatment.